So our good friend Howard Wolinsky has just written up his assessment on the evolution of the use of the PSA test in “screening” for prostate cancer in an article on the MedPage Today web site. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: PSA, risk, screening, test | 17 Comments »
A newly published article by Shoag et al. in the New England Journal of Medicine (NEJM) has suggested that the risks associated with “screening” for prostate cancer using the PSA test may not be as high as previously suggested. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: benefit, PSA, risk, screening, test | 4 Comments »
It will come as no surprise to the well-informed that if you are taking a 5-alpha-reductase inhibitor (a 5-ARI) like dutasteride or finasteride for benign prostatic hyperplasia (BPH), it significantly lowers your “normal” PSA level (to about half the actual value). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: 5-ARI, Diagnosis, dutasteride, finasteride, PSA, risk | 12 Comments »
According to a report on the US Food and Drug Administration (FDA) web site, the FDA has just approved the “finger-prick” Sangia Total PSA blood test developed by OPKO Diagnostics. … READ MORE …
Filed under: Uncategorized | Tagged: finger-prick, OPKO, PSA, Sangia | 3 Comments »
So first the “less good” news … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: OPKO, point of care, PSA, Sangia, test | 6 Comments »
Last week we noted that adding MRI data to the Partin tables and to the Kattan/MSKCC nomograms did not seem to improve the accuracy of prognosis of outcomes after radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, clinically significant, data, Gleason 7, MRI, outcome, PI-RADS, prediction, PSA, risk | 5 Comments »
The Prostate Cancer Foundation posted two useful and basic articles on its blog site this December that may be useful resources for men concerned about their risk for or newly diagnosed with prostate cancer or monitoring their PSA over time (for any one of all sorts of possible reasons). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: accuracy, advice, diagnosed, guidance, newly, PSA, test | 4 Comments »
A newly published paper has now suggested that data from a single PSA test carried out when the men are between 40 and 64 years of age can be used to project risk for aggressive prostate cancer among African-American men. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: African=American, black, PSA, risk, testing | 2 Comments »
A new and potentially controversial article in Urology (the “Gold Journal”) has just suggested that regular, mass, population-based screening of men for risk of prostate cancer every 12 to 18 months remains a good idea. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Management, PSA, risk, screening, testing | 9 Comments »
Researchers at the University of Adelaide in South Australia have shown that that there is an inverse relationship between PSA levels in the blood and the body mass of the men being tested. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: obesity, PSA, risk | 3 Comments »
A while ago now we had first mentioned the “Cluster randomized trial of PSA testing for prostate cancer” or CAP trial — the single largest randomized trial of PSA screening for risk of prostate cancer to be implemented. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: PSA, risk, screening, test | 18 Comments »
Data from the ongoing, prospective IMPACT study has shown that PSA velocity is not predictive of risk for a positive prostate cancer biopsy result in men who are carriers of the BRCA2 gene. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: BRCA1/2, gene, hereditary, PSA, risk, status, velocity | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 